Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“it's our joint venture with another public RIET ARE in South San Francisco, where we have a large building that was developed a few years ago that is available for lease”
BXP holds a life-science joint venture with Alexandria Real Estate (ARE) in South San Francisco where a large building remains available amid tepid wet-lab demand.
“651 Gateway, again, we're going by Alexandria's accounting for when it comes into service, we would have already put into service based upon our accounting, but that's the way they do things.”
BXP defers to joint-venture partner Alexandria Real Estate Equities' accounting convention for when the 651 Gateway life-science development is placed into service, delaying its stabilization timeline versus BXP's own methodology.
“Where we're going to have, I'd say a more of a challenge are at 651 Gateway, which is the building we have with ARE where there's very little activity right now.”
BXP's 651 Gateway lab building, a joint venture with Alexandria Real Estate Equities (ARE) in South San Francisco, is seeing very little leasing activity, one of BXP's more challenged development assets.
“Pinterest terminated their lease with us in 2020 and paid us an $89.5 million fee.”
Pinterest was a former Alexandria tenant at the 88 Bluxome Street site who exited its lease early, paying a termination fee; reflects a past tenant loss rather than current demand.
“UCSF is a big tenant on campus and sometimes their needs flex between lab and office.”
UCSF is a major Alexandria tenant at Mission Bay whose flexing lab/office needs support the move toward office-use flexibility.
“Clearly, OpenAI has made that the center of the universe for their needs and campuses buildings around a campus, and that's a very valuable use of space.”
Alexandria cites OpenAI's Mission Bay office demand as a valuable driver behind its move to obtain office (Prop M) flexibility for its buildings.
“probably the next biggest company, which is maybe, I don't know, 1/4 of our size or something like that, 1/3 of our size is, Blackstone, and they're private, obviously, and they have a very different mindset about how they run their business”
Alexandria names Blackstone as its next-largest life-science real estate competitor but frames it as a smaller, purely financial player with a different approach.
“What I wanted to point out is that, that opportunity really aligns well with the ongoing development we have going on at the same campus with Bristol-Myers.”
Bristol-Myers Squibb is expanding at ARE's Campus Point Megacampus in San Diego alongside a newly signed multinational pharma lease, reinforcing demand for ARE's flagship life-science campus.
“Examples include AbbVie's acquisition of a company called Capstone an early clinical stage company developing novel mRNA therapies for autoimmune diseases such as severe lupus, signaling that pharma is ready and willing to buy cutting-edge science.”
ARE cites AbbVie's acquisition of clinical-stage biotech Capstone as evidence that large pharma remains willing to pay up for early-stage science, a tailwind for ARE's life-science tenant base and future leasing demand.
“tenant Eli Lilly's recently announced clinical data on a new type of weight loss medicine that would come in a pill.”
Eli Lilly, an Alexandria tenant, is cited for positive new clinical data on an oral weight-loss drug, used as an example of the innovation pipeline supporting demand for life-science real estate.
“we established a relationship with Alnylam 2003 and today that company is now a big biotech occupying huge amount of swath of real estate in Cambridge.”
Alnylam, an early-relationship tenant dating to 2003 when it was a small biotech, is cited as a success story now occupying a large amount of Alexandria's Cambridge real estate.
“Moderna's move out of Alexandria Technology Square to the new HQ R&D campus we developed for them at 325 Binney”
Moderna relocated from Alexandria Technology Square into a dedicated new HQ R&D campus Alexandria built for them at 325 Binney, reflecting Moderna's continued growth even as the vacated space weighed on Alexandria's near-term occupancy.
“Matimco secured a 580,000 square foot 15-year laboratory office lease with Biogen at their large-scale Volpe site in East Cambridge.”
Biogen signed a large 15-year, 580,000-square-foot lab/office lease at above-market rent ($136 triple net) in East Cambridge, cited as evidence of high-quality tenant demand for premium locations.
“led by our 400-tech square lease with Intellia, a leading gene therapy company developing the next generation of treatments for rare disease.”
Intellia signed a major new lease that led Alexandria's public-biotech leasing segment this quarter, reflecting continued strong demand from well-capitalized public biotechs.
“First $40.9 million for properties at One Moderna Way and Route 128, which was sold to our longstanding tenant for $369.4 million during the quarter.”
Alexandria sold the One Moderna Way/Route 128 property to its longstanding tenant Moderna for $369.4 million during the quarter, recognizing a related impairment on the disposed asset.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Vikram Malhotra | Mizuho Securities | 13 (38%) |
| Rich Anderson | Wedbush Securities | 12 (0%) |
| Tony Paolone | JPMorgan | 11 (0%) |
| Jim Kammert | Evercore ISI | 11 (0%) |
| Mike Carroll | RBC Capital Markets | 11 (0%) |
| Farrell Granath | Bank of America | 10 (0%) |
| Nick Joseph | Citigroup | 9 (0%) |
| Dylan Burzinski | Green Street | 8 (13%) |
| Omotayo Okusanya | Deutsche Bank | 7 (0%) |
| Wes Golladay | Robert W. Baird | 6 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Evercore ISI | 2 | 13 (0%) |
| Mizuho Securities | 1 | 13 (38%) |
| Wedbush Securities | 1 | 12 (0%) |
| RBC Capital Markets |
| 1 |
| 11 (0%) |
| JPMorgan | 1 | 11 (0%) |
| Bank of America | 1 | 10 (0%) |
| Citigroup | 1 | 9 (0%) |
| Green Street | 1 | 8 (13%) |
Alexandria closed FY2025 with FFO of $9.01 per share at the midpoint of prior guidance, while executing $1.5 billion in Q4 dispositions across 26 transactions and recognizing $1.45 billion in impairments to accelerate the non-core exit strategy. Q4 leasing of 1.2 million square feet was the highest in a year, with vacant space absorption nearly doubling the recent quarterly average, but public biotech demand remained critically absent. Management introduced FY2026 FFO guidance of $6.40 at the December Investor Day, reflecting significant near-term headwinds from 1.2 million square feet of known vacates and reduced capitalized interest, while projecting occupancy recovery in the second half of 2026 and a 2-3 year timeline for core market fundamentals to normalize.
Demand | Capital Allocation | Capex Investment | Competitive Dynamics | Regulation Policy | Credit | Pricing | Margin | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 9 | 5 | 3 | 4 | 2 | 2 | 1 | 1 |
| 2025Q1 | 8 | 5 | 4 | 2 | 2 | |||
| 2025Q2 | 8 | 3 | 6 | 1 | 2 | 2 | ||
| 2025Q3 | 10 | 10 | 3 | 3 | 1 | 1 | 2 | 1 |
| 2025Q4 | 9 | 5 | 3 | 3 | 1 | 2 | 1 | 2 |
| 2026Q1 | 13 | 5 | 4 | 1 | 2 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 9 | 8 | 8 | 10 | 9 | 13 |
| Capital Allocation | 5 | 5 | 3 | 10 | 5 | 5 |
| Capex Investment | 3 | 4 | 6 | 3 | 3 | 4 |
| Competitive Dynamics | 4 | 1 | 3 | 3 | 1 | |
| Regulation Policy | 2 | 2 | 2 | 1 | 1 | 2 |
| Credit | 2 | 2 | 1 | 2 | 2 | |
| Pricing | 1 | 2 | 2 | 1 | ||
| Margin | 1 | 1 | 2 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ARE Alexandria Real Estate Equities | 2 | -9.7% | |
| BXP BXP, Inc. | 6 | +0.8% | |
| DLR Digital Realty | 8 | +12.0% |